Supersaturated oxygen New Innovation in acute Heart Attack: AMIHOT II Trial

Since the introduction of primary percutaneous coronary intervention (PCI), the technology and innovation seem to get stuck at its efforts to reduce the infarct size after myocardial infarction (MI). The infarct size has been directly related to adverse events and all-cause mortality, both immediate and delayed. A number of device based cardiac protection has been tried in the past after an acute MI and although observational studies have shown the same benefit large randomized trials have failed to show improvement in clinical outcomes or reduction in infarct size.

Thrombus aspiration, thrombectomy, and distal protection devices have failed to meet the expectations. Intralesional GPIIB/IIIA inhibitors through a device have shown some possible beneficial effects but no randomized data is been proven. The MGuard and MGuard Prime are embolic protection stents shows success in observational data but lack randomized control.

In this era of intervention, now supersaturated oxygen delivery through a device has been found to be very effective in AMIHOT II. The supersaturated oxygen at the pressure of 760 to 1000 mm Hg has been intracoronary infused after stent implantation.

400 patients with internal STEMI involving left anterior descending artery (LAD) were randomized 1:1 into primary PCI and primary PCI plus supersaturated oxygen and found to be effective. One such device TherOx received FDA approval for heart attack treatment to reduce infarct size. This therapy has to be adjunctively administered immediately following successful stent implantation without delay.

A heart attack is typically caused when blood and oxygen flow to the heart is blocked or reduced and the heart’s tiny capillaries swell, further restricting blood flow. If not quickly restored, irreversible damage to the heart muscle, or infarction, will occur. SSO2 Therapy is based on the known benefits of hyperbaric oxygen treatment in improving the body’s ability to heal. SSO2 Therapy infuses super-oxygenated blood to improve microvascular flow and has been shown to save heart muscle by reducing infarct size. Immediately after the coronary artery has been opened by PCI, SSO2 Therapy delivers a one-time, 60-minute infusion of the patient’s super-oxygenated blood to the targeted ischemic area of the heart through a small catheter. The super-oxygenated blood helps reduce capillary swelling to restore blood flow to the surrounding tissue and decrease infarct size.7,8 SSO2 Therapy is aligned with current guidelines for interventional cardiology procedures.